Skip to main content

What the FDA labels say about taking them together

Cisplatin and rituximab

Rituximab's FDA label of January 6, 2025 names cisplatin in its drug interactions section; the cisplatin label PlainMeds reads does not name rituximab. The rituximab label: “Renal toxicity when used in combination with cisplatin.”

Check it at the source: the cisplatin FDA label on DailyMed (effective September 16, 2021, WG Critical Care, LLC); the rituximab FDA label on DailyMed (effective January 6, 2025, Genentech, Inc.).

What does the cisplatin label say about rituximab?

Cisplatin's label (effective September 16, 2021) does not name rituximab in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (CISplatin), NDA018057 (Hq Spclt Pharma), as published by WG Critical Care, LLC, effective September 16, 2021 (SPL set 2bf8d2fb-80c8-401d-8e9b-d58463f5e954), via openFDA; the full label on DailyMed

What does the rituximab label say about cisplatin?

Rituximab label, drug interactions

Renal toxicity when used in combination with cisplatin ( 5.8 ).

Rituximab label, warnings and precautions

Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials.

Source: FDA drug label (Rituxan), Genentech, Inc., effective January 6, 2025 (SPL set b172773b-3905-4a1c-ad95-bab4b6126563), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

9Cisplatin generic labelers
0Rituximab generic labelers
CisplatinRituximab
Labeled forn/aLeukemia, lymphoma and myeloma, Rheumatoid arthritis
Boxed warningYesYes
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?